Global Breakthrough Therapy (BT) Designation Market Size, Status and Forecast 2021-2027

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Breakthrough Therapy (BT) Designation Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
  • 1.2.2 Oncology
  • 1.2.3 Infectious Diseases
  • 1.2.4 Rare Diseases
  • 1.2.5 Autoimmune Diseases
  • 1.2.6 Pulmonary Diseases
  • 1.2.7 Neurological Disorders
  • 1.2.8 Others
• 1.3 Market by Application
  • 1.3.1 Global Breakthrough Therapy (BT) Designation Market Share by Application: 2016 VS 2021 VS 2027
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Research Institute
  • 1.3.5 Laboratories
  • 1.3.6 Others
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Breakthrough Therapy (BT) Designation Market Perspective (2016-2027)
• 2.2 Breakthrough Therapy (BT) Designation Growth Trends by Regions
  • 2.2.1 Breakthrough Therapy (BT) Designation Market Size by Regions: 2016 VS 2021 VS 2027
  • 2.2.2 Breakthrough Therapy (BT) Designation Historic Market Share by Regions (2016-2021)
  • 2.2.3 Breakthrough Therapy (BT) Designation Forecasted Market Size by Regions (2022-2027)
• 2.3 Breakthrough Therapy (BT) Designation Industry Dynamic
  • 2.3.1 Breakthrough Therapy (BT) Designation Market Trends
  • 2.3.2 Breakthrough Therapy (BT) Designation Market Drivers
  • 2.3.3 Breakthrough Therapy (BT) Designation Market Challenges
  • 2.3.4 Breakthrough Therapy (BT) Designation Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Breakthrough Therapy (BT) Designation Players by Revenue
  • 3.1.1 Global Top Breakthrough Therapy (BT) Designation Players by Revenue (2016-2021)
  • 3.1.2 Global Breakthrough Therapy (BT) Designation Revenue Market Share by Players (2016-2021)
• 3.2 Global Breakthrough Therapy (BT) Designation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Breakthrough Therapy (BT) Designation Revenue
• 3.4 Global Breakthrough Therapy (BT) Designation Market Concentration Ratio
  • 3.4.1 Global Breakthrough Therapy (BT) Designation Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Breakthrough Therapy (BT) Designation Revenue in 2020
• 3.5 Breakthrough Therapy (BT) Designation Key Players Head office and Area Served
• 3.6 Key Players Breakthrough Therapy (BT) Designation Product Solution and Service
• 3.7 Date of Enter into Breakthrough Therapy (BT) Designation Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Breakthrough Therapy (BT) Designation Breakdown Data by Type

• 4.1 Global Breakthrough Therapy (BT) Designation Historic Market Size by Type (2016-2021)
• 4.2 Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Type (2022-2027)

5 Breakthrough Therapy (BT) Designation Breakdown Data by Application

• 5.1 Global Breakthrough Therapy (BT) Designation Historic Market Size by Application (2016-2021)
• 5.2 Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Application (2022-2027)

6 North America

• 6.1 North America Breakthrough Therapy (BT) Designation Market Size (2016-2027)
• 6.2 North America Breakthrough Therapy (BT) Designation Market Size by Type
  • 6.2.1 North America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021)
  • 6.2.2 North America Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027)
  • 6.2.3 North America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027)
• 6.3 North America Breakthrough Therapy (BT) Designation Market Size by Application
  • 6.3.1 North America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021)
  • 6.3.2 North America Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027)
  • 6.3.3 North America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027)
• 6.4 North America Breakthrough Therapy (BT) Designation Market Size by Country
  • 6.4.1 North America Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021)
  • 6.4.2 North America Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027)
  • 6.4.3 United States
  • 6.4.3 Canada

7 Europe

• 7.1 Europe Breakthrough Therapy (BT) Designation Market Size (2016-2027)
• 7.2 Europe Breakthrough Therapy (BT) Designation Market Size by Type
  • 7.2.1 Europe Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021)
  • 7.2.2 Europe Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027)
  • 7.2.3 Europe Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027)
• 7.3 Europe Breakthrough Therapy (BT) Designation Market Size by Application
  • 7.3.1 Europe Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021)
  • 7.3.2 Europe Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027)
  • 7.3.3 Europe Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027)
• 7.4 Europe Breakthrough Therapy (BT) Designation Market Size by Country
  • 7.4.1 Europe Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021)
  • 7.4.2 Europe Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic

8 Asia-Pacific

• 8.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size (2016-2027)
• 8.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type
  • 8.2.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021)
  • 8.2.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027)
  • 8.2.3 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027)
• 8.3 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application
  • 8.3.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021)
  • 8.3.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027)
  • 8.3.3 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027)
• 8.4 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region
  • 8.4.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region (2016-2021)
  • 8.4.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region (2022-2027)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Breakthrough Therapy (BT) Designation Market Size (2016-2027)
• 9.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Type
  • 9.2.1 Latin America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021)
  • 9.2.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027)
  • 9.2.3 Latin America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027)
• 9.3 Latin America Breakthrough Therapy (BT) Designation Market Size by Application
  • 9.3.1 Latin America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021)
  • 9.3.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027)
  • 9.3.3 Latin America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027)
• 9.4 Latin America Breakthrough Therapy (BT) Designation Market Size by Country
  • 9.4.1 Latin America Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021)
  • 9.4.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size (2016-2027)
• 10.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type
  • 10.2.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021)
  • 10.2.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027)
  • 10.2.3 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027)
• 10.3 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application
  • 10.3.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021)
  • 10.3.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027)
  • 10.3.3 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027)
• 10.4 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country
  • 10.4.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021)
  • 10.4.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Roche
  • 11.1.1 Roche Company Details
  • 11.1.2 Roche Business Overview
  • 11.1.3 Roche Breakthrough Therapy (BT) Designation Introduction
  • 11.1.4 Roche Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.1.5 Roche Recent Development
• 11.2 Abbvie
  • 11.2.1 Abbvie Company Details
  • 11.2.2 Abbvie Business Overview
  • 11.2.3 Abbvie Breakthrough Therapy (BT) Designation Introduction
  • 11.2.4 Abbvie Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.2.5 Abbvie Recent Development
• 11.3 Novartis International AG
  • 11.3.1 Novartis International AG Company Details
  • 11.3.2 Novartis International AG Business Overview
  • 11.3.3 Novartis International AG Breakthrough Therapy (BT) Designation Introduction
  • 11.3.4 Novartis International AG Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.3.5 Novartis International AG Recent Development
• 11.4 Janssen
  • 11.4.1 Janssen Company Details
  • 11.4.2 Janssen Business Overview
  • 11.4.3 Janssen Breakthrough Therapy (BT) Designation Introduction
  • 11.4.4 Janssen Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.4.5 Janssen Recent Development
• 11.5 BMS
  • 11.5.1 BMS Company Details
  • 11.5.2 BMS Business Overview
  • 11.5.3 BMS Breakthrough Therapy (BT) Designation Introduction
  • 11.5.4 BMS Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.5.5 BMS Recent Development
• 11.6 Eli Lilly
  • 11.6.1 Eli Lilly Company Details
  • 11.6.2 Eli Lilly Business Overview
  • 11.6.3 Eli Lilly Breakthrough Therapy (BT) Designation Introduction
  • 11.6.4 Eli Lilly Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.6.5 Eli Lilly Recent Development
• 11.7 Gilead
  • 11.7.1 Gilead Company Details
  • 11.7.2 Gilead Business Overview
  • 11.7.3 Gilead Breakthrough Therapy (BT) Designation Introduction
  • 11.7.4 Gilead Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.7.5 Gilead Recent Development
• 11.8 Sanofi
  • 11.8.1 Sanofi Company Details
  • 11.8.2 Sanofi Business Overview
  • 11.8.3 Sanofi Breakthrough Therapy (BT) Designation Introduction
  • 11.8.4 Sanofi Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.8.5 Sanofi Recent Development
• 11.9 Regeneron
  • 11.9.1 Regeneron Company Details
  • 11.9.2 Regeneron Business Overview
  • 11.9.3 Regeneron Breakthrough Therapy (BT) Designation Introduction
  • 11.9.4 Regeneron Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.9.5 Regeneron Recent Development
• 11.10 Acadia
  • 11.10.1 Acadia Company Details
  • 11.10.2 Acadia Business Overview
  • 11.10.3 Acadia Breakthrough Therapy (BT) Designation Introduction
  • 11.10.4 Acadia Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.10.5 Acadia Recent Development
• 11.11 Boehringer Ingelheim
  • 11.11.1 Boehringer Ingelheim Company Details
  • 11.11.2 Boehringer Ingelheim Business Overview
  • 11.11.3 Boehringer Ingelheim Breakthrough Therapy (BT) Designation Introduction
  • 11.11.4 Boehringer Ingelheim Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.11.5 Boehringer Ingelheim Recent Development
• 11.12 Amgen
  • 11.12.1 Amgen Company Details
  • 11.12.2 Amgen Business Overview
  • 11.12.3 Amgen Breakthrough Therapy (BT) Designation Introduction
  • 11.12.4 Amgen Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.12.5 Amgen Recent Development
• 11.13 AstraZeneca
  • 11.13.1 AstraZeneca Company Details
  • 11.13.2 AstraZeneca Business Overview
  • 11.13.3 AstraZeneca Breakthrough Therapy (BT) Designation Introduction
  • 11.13.4 AstraZeneca Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.13.5 AstraZeneca Recent Development
• 11.14 GlaxoSmithKline
  • 11.14.1 GlaxoSmithKline Company Details
  • 11.14.2 GlaxoSmithKline Business Overview
  • 11.14.3 GlaxoSmithKline Breakthrough Therapy (BT) Designation Introduction
  • 11.14.4 GlaxoSmithKline Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.14.5 GlaxoSmithKline Recent Development
• 11.15 Vertex
  • 11.15.1 Vertex Company Details
  • 11.15.2 Vertex Business Overview
  • 11.15.3 Vertex Breakthrough Therapy (BT) Designation Introduction
  • 11.15.4 Vertex Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.15.5 Vertex Recent Development
• 11.16 Alexion
  • 11.16.1 Alexion Company Details
  • 11.16.2 Alexion Business Overview
  • 11.16.3 Alexion Breakthrough Therapy (BT) Designation Introduction
  • 11.16.4 Alexion Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.16.5 Alexion Recent Development
• 11.17 Merck
  • 11.17.1 Merck Company Details
  • 11.17.2 Merck Business Overview
  • 11.17.3 Merck Breakthrough Therapy (BT) Designation Introduction
  • 11.17.4 Merck Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.17.5 Merck Recent Development
• 11.18 Jazz Pharmaceuticals
  • 11.18.1 Jazz Pharmaceuticals Company Details
  • 11.18.2 Jazz Pharmaceuticals Business Overview
  • 11.18.3 Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Introduction
  • 11.18.4 Jazz Pharmaceuticals Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.18.5 Jazz Pharmaceuticals Recent Development
• 11.18 Exelixis

.1 Exelixis Company Details

.2 Exelixis Business Overview

.3 Exelixis Breakthrough Therapy (BT) Designation Introduction

.4 Exelixis Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)

.5 Exelixis Recent Development

• 11.20 Eisai
  • 11.20.1 Eisai Company Details
  • 11.20.2 Eisai Business Overview
  • 11.20.3 Eisai Breakthrough Therapy (BT) Designation Introduction
  • 11.20.4 Eisai Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.20.5 Eisai Recent Development
• 11.21 Takeda
  • 11.21.1 Takeda Company Details
  • 11.21.2 Takeda Business Overview
  • 11.21.3 Takeda Breakthrough Therapy (BT) Designation Introduction
  • 11.21.4 Takeda Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.21.5 Takeda Recent Development
• 11.22 Pfizer
  • 11.22.1 Pfizer Company Details
  • 11.22.2 Pfizer Business Overview
  • 11.22.3 Pfizer Breakthrough Therapy (BT) Designation Introduction
  • 11.22.4 Pfizer Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
  • 11.22.5 Pfizer Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer